A small pilot study involving patients with brain and/or spinal cord lymphoma showed:
"For many patients with lymphoma"There are no suitable treatment options for the central nervous system," said Dana-Farber's Caron Jacobson, MD, who led the project. “The study results showed that the use of CAR-T cells will make a difference.”
Lymphomas are usually characterized by aggressivetumors that spread to the brain and spinal cord after they have arisen in other parts of the body. These cancers are often difficult to treat, and patients rarely live more than two years after diagnosis.
CAR-T cells are genetically reprogrammed tothey bound to tumors and destroyed them. They have already proven effective in treating other forms of lymphoma. Scientists have now begun a pilot clinical trial to evaluate the safety of axi-cel treatment in brain and spinal cord cancers.
The study included nine patients, 78% of whom had tumors that shrank or disappeared as a result of treatment.
During the experiment, scientists identified andanalyzed both CAR and non-CAR T cells. They used advanced techniques, including RNA sequencing. In total, the researchers analyzed more than 125,000 individual cells. The biologists also identified a molecular signature unique to CAR-T cells. It may be critical for controlling the antitumor response in brain and spinal cord cancers.
Read more:
Hydrogen energy, material against cold weather and bioadditives against COVID-19: what scientists are creating in the North
10 scientific facts that turned out to be fakes. Cards
Unusual decoration in an ancient grave surprised scientists